Accelerating Clinical Trials in Parkinson's

Co-led by University College London and University of Plymouth, in collaboration with the MRC Clinical Trials Unit at UCL

What is EJS ACT-PD?

This video provides an introduction to the EJS ACT-PD Initiative from our project co-leads: Professor Tom Foltynie (University College London) and Professor Camille Carroll (University of Plymouth).

(Subtitles available by clicking on the icon at the bottom of the video)

Latest Updates

Annual Event 2023

 Thank you to everyone that joined us at the EJS ACT-PD Annual Event 2023! It was brilliant to hear from our Working Group chairs about all of the excellent progress each group has made over the past year. The day also included exciting updates on how our patient and public input has impacted our trial decisions so far, our communications strategy and possible exploratory outcome measures. This was a great chance to set the scene for another exciting year in which we will work towards trial delivery and launch!

EJS ACT-PD Present at the PD Frontline Webinar

Check out EJS ACT-PD presenting at the PD Frontline Webinar: ‘Trials and the Parkinson’s Community’. We presented an overview of the project, and why having people with Parkinson’s and their care partners involved in all aspects of research is so important!

The full recording is now available on YouTube via the following link:


World Parkinson Congress

The EJS ACT-PD team were delighted to present 7 posters this July at the World Parkinson Congress 2023 held in Barcelona. This was a brilliant opportunity to share our progress to date and to learn more about many other brilliant initiatives and communities within the world of Parkinson’s. All 7 posters can be found on our poster gallery page.

Project Overview

The EJS ACT-PD Consortium is comprised of 6 Working Groups, an overarching Steering Group and an International Advisory Group. Whilst each Working Group is focused on a specific element of the project, they work collaboratively to reach consensus on all decisions made.

Associated Partners